<> <> <> <>
Latest Research

Real-world results from Juniper’s digital weight loss programme in the UK

Understanding the effectiveness and care continuity of a GLP-1 RA-supported digital weight loss programme in the United Kingdom

Published in the Journal of Diabetes, Obesity and Metabolism
Medically reviewed by
Dr Louis Talay
Dr Matthew Vickers
Last updated
12
December
,
2024
3 min read
link copied

Key takeaways

  • Juniper UK patients lost an average of 10.73% of their total body weight in 5 months.
  • About 82% of patients lost at least 5% of their baseline weight, 52% lost at least 10%, and 23% lost at least 15%.
  • Patients used an app for quick access to their healthcare team, particularly for managing potential side effects.
  • The average patient received five messages a month and the median response time to adverse events was 14 hours.

How much weight do Juniper UK patients lose?

Research published in the Journal of Diabetes, Obesity and Metabolism demonstrated that UK-based patients on Juniper’s digital weight loss programme experienced significant weight loss.

Among the participants who completed the study, 82.36% lost at least 5% of their baseline weight, 52.07% lost at least 10%, and 23.22% lost at least 15%.

Juniper’s continuity of care

This study’s care continuity claims are the first of their kind. While weight loss outcomes are important when assessing the success of a programme, it’s vital that patients feel supported by their multidisciplinary team throughout their care journey.

In this study, participants made use of an app, which provided quick access to the team of healthcare professionals managing their treatment. This was a particularly reassuring feature for those who required support to manage any potential unpleasant side effects.

Patients maintained ongoing contact with their support team, receiving coaching on making and maintaining the healthy lifestyle changes required to achieve long-term weight loss. The average patient received five messages per month from their multidisciplinary care team, with the median response time to adverse events being 14 hours.

Limitations of this study

This study reported a relatively high drop-out rate, meaning that several patients were not included in the final analysis because they didn't satisfy the study criteria. This is a common finding in studies of real-world chronic care interventions, as everyday challenges such as work and family commitments affect a patient's capacity to upload data within a specific study timeframe.

Understanding adherence

How long did patients stay on the Juniper UK programme and why did they stop?

To gain a proper understanding of Juniper drop-out patterns, investigators conducted a dedicated adherence study, published in the Journal of Community Medicine & Public Health.

This study found that the average Juniper patient stays on the programme for six months (183 days).

The most common reasons for discontinuation were programme cost (38.7%), dissatisfaction with results (16.8%), intolerable side effects (15.4%), weight loss goal achieved (7.3%) and temporary hiatus/going on holiday (5.6%).

For further insights from our patients, visit our Testimonials page and hear real-life accounts from patients who stayed with Juniper and successfully achieved their weight loss and health goals.

Medically reviewed by

Dr Louis Talay
Medical Research Lead | Eucalyptus
Dr Matthew Vickers
Clinical Director | Eucalyptus

Explore more research

GER
Journal of Obesities
L. Talay
M. Vickers
L. Ruiz

Real-world results from Juniper’s digital weight loss service in Germany

July 24, 2024
UK
Telemedicine Reports
L. Talay
M. Vickers
C. Bell
T. Galvin

Real-world results with patients on tirzepatide in Juniper UK’s comprehensive program

November 8, 2024